AREC.L

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Arecor Therapeutics plc

Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.

www.arecor.com

Employees: 33
IPO / List date: Jun 3, 2021
HQ: GB

Held by traders on TradeandTell

No one on the platform currently holds AREC.L.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in AREC.L as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded AREC.L yet.